Direct-to-patient logistics services
Patient enrollment and retention can be a quite a challenge when dealing with homebound patients, an orphan indication, or a dispersed patient population. CSM has designed a Direct-to-Patient program, which provides a highly customizable solution per patient and per protocol. CSM is ahead of the others in the clinical trial logistics industries; siteless trials are trending and we have worked tirelessly to provide first-rate direct-to-patient logistics services.
With a 10+ year track record in Direct-to-Patient, we have delivered over 7,000 DtP shipments to trial participants.
By meticulously designing these projects, we ensure our clients and their contractors are following the guidelines of GCP. Our team creates an individual logistics plan for each patient location to ensure smooth delivery and compliance.
CSM is carrier neutral and our Direct-to-Patient logistics pre-planning ensure your products are delivered at the right temperature and within the right guidelines.
Throughout each stage of the supply chain, CSM ensures the privacy of patients, protecting patient health information.
>> For more information about how CSM’s Direct-to-Patient (DtP) platform is a patient-centric approach to the clinical supply shipping process, read our article titled Adopting Direct-to-Patient Methods in Clinical Trials.
Direct-To-Patient Logistics Benefits:
- Gain Access to a Wider Patient Population
- Increase Patient Enrollment and Retention
- Reduce Patient Trips to Clinical Sites
- Use of Integrated Courier Sites
When used in conjunction with On-Demand Packaging and Labeling, CSM is able to dispense daily dosing for a product that has a very short shelf life. These innovative services are truly setting the pathway for personalized medicine.
>> Read this Case Study to learn more about CSM’s Direct-to-Patient Shipping services. The study explains how CSM was faced with an incredibly complicated study and took the time to create a solution that was not only effective, but also revolutionary.